Improved Lung Function is Associated With Better Asthma Control in Children Aged 6 to 11 Years With Moderate-To-Severe Type 2 Asthma: A Post Hoc Analysis of VOYAGE

Leonard B. Bacharier, Division of Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr Children’s Hospital at Vanderbilt University Medical Center, Nashville, TN, United States; Sharon Dell, BC Children’s Hospital, Vancouver, BC, Canada; Ines De Mir, Hospital Universitari Vall hebron, Barcelona, Catalonia, Spain; Giorgio Piacentini, University of Verona, Verona, Veneto, Italy; Eckard Hamelmann, Kinderzentrum Bethel, Univ.-Klinik für Kinder- und Jugendmedizin, Universität Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany; Jérôme Msihid, Sanofi, Gentilly, Ile-de-France, France; Rebecca Gall, Regeneron Pharmaceuticals, Tarrytown, NY, United States; Olivier LEDANOIS, SANOFI, Paris, Ile-de-France, France; Zhixiao Wang, Regeneron, Sleepy Hollow, NY, United States; Wendy (Wei-Han) Cheng, Sanofi, Glenview, IL, United States; Harry Sacks, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States; Juby Anne. Jacob-Nara, Sanofi, Hillsborough, NJ, United States; Paul J Rowe, Sanofi, Bridgewater, NJ, United States; Erik Orava, Sanofi, Mississauga, ON, Canada; Yamo Deniz, Regeneron Pharmaceuticals, Naples, FL, United States